Compare RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) (RELX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) vs Twist Bioscience Corp — how do they compare? RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) trades at $36.73 (market cap $63.57B), while Twist Bioscience Corp trades at $146.57 (market cap $10.03B). The key difference: RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) is far larger — about 6.3× Twist Bioscience Corp's market cap, and RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) pays a 2.49% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| RELX | TWST | |
|---|---|---|
Market Cap | $63.57B | $10.03B |
Volume | 1,602,093 | 1,528,940 |
Sector | Industrials | Health |
52-Week High | $46.80 | $205.00 |
52-Week Low | $27.73 | $25.45 |
Enterprise Value | $75.05B | $9.96B |
Dividend Yield | 2.49% | — |
Typical Hold Time | — | 27 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RELX trades at $36.70, up 0.44% with neutral technical signals. The company demonstrates strong profitability with 23.27% net margins and 132.36% ROE, though valuation metrics appear elevated with P/E of 22.21 and P/B of 38.89. Recent earnings show mixed results with Q2 2026 beating expectations while Q4 2025 missed. Analyst sentiment remains positive with 71% buy ratings and consensus price target of $26.00.
The investment case balances strong fundamentals against premium valuation. Growth catalysts include AI-driven product adoption and margin expansion, while risks involve competitive pressures and valuation concerns. With solid cash flow generation and institutional support, RELX offers quality exposure but requires monitoring of valuation multiples and competitive dynamics.
TWST trades at $148.16, down 2.44% today, with a bullish technical signal but negative earnings trends. Recent news highlights its role in Eli Lilly's AI drug discovery platform, driving investor optimism. Revenue growth is strong, reaching $376.57M in 2025, but net losses persist, with a margin of -20.63%. The stock faces resistance near $154, with support at $146.
Outlook is mixed: analyst consensus is bullish with a $153.70 price target, but profitability challenges and cash flow deficits pose risks. The AI collaboration offers growth potential, yet execution and margin improvement are critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share)
RELX PLC is a UK-based information and analytics company operating across four segments: Risk (fraud prevention and compliance analytics via LexisNexis Risk Solutions), Scientific, Technical & Medical (Elsevier's research and clinical content), Legal (LexisNexis Legal & Professional's research tools), and Exhibitions (RX's trade events). It serves professional, business, and government customers worldwide.
Read more on RELX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
